Cytosorbents CorpCTSO
CTSO
About: CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Employees: 149
0
Funds holding %
of 7,323 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 9
19% more capital invested
Capital invested by funds: $14.1M [Q4 2024] → $16.8M (+$2.71M) [Q1 2025]
14% more call options, than puts
Call options by funds: $8K | Put options by funds: $7K
2.74% more ownership
Funds ownership: 27.96% [Q4 2024] → 30.7% (+2.74%) [Q1 2025]
6% less funds holding
Funds holding: 50 [Q4 2024] → 47 (-3) [Q1 2025]
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$1
9%
upside
Avg. target
$5.50
498%
upside
High target
$10
987%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
D. Boral Capital Jason Kolbert | 987%upside $10 | Buy Maintained | 21 Jul 2025 |
HC Wainwright & Co. Sean Lee | 9%upside $1 | Neutral Reiterated | 15 May 2025 |
Financial journalist opinion
Neutral
PRNewsWire
1 day ago
CytoSorbents to Report Second Quarter 2025 Financial Results and Recent Business Highlights
PRINCETON, N.J. , July 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2025 financial results and recent business highlights after the market close on Thursday, August 7, 2025.
Neutral
PRNewsWire
4 weeks ago
CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR
PRINCETON, N.J. , July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and Health Canada.
Neutral
PRNewsWire
1 month ago
CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR
PRINCETON, N.J. , June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for supervisory review (administrative appeal) with the U.S. Food and Drug Administration (FDA) under 21 CFR 10.75, of the De Novo Denial Letter issued on April 25, 2025 for CytoSorbents' DrugSorb-ATR Device, (the denial letter).
Neutral
PRNewsWire
2 months ago
CytoSorbents to Participate at the Jefferies Global Healthcare Conference
PRINCETON, N.J. , May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference in New York, NY on June 4 – 5, 2025.
Neutral
PRNewsWire
2 months ago
CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J. , May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today's presentation at EuroPCR 2025 of a new contemporary real-world data analysis highlighting the intraoperative use of its technology to significantly reduce the severity of bleeding in urgent coronary artery bypass grafting (CABG) patients on the blood thinner, ticagrelor (Brilinta®, AstraZeneca) who had not completed the recommended drug washout period.
Neutral
Seeking Alpha
2 months ago
Cytosorbents Corporation (CTSO) Q1 2025 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Adanna Alexander - Investor Relations Phillip Chan - Chief Executive Officer Makis Deliargyris - Chief Medical Officer Pete Mariani - Chief Financial Officer Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C. Wainwright Michael Kim - Zacks Small-Capital Research Operator Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents First Quarter 2025 Earnings Conference Call.
Neutral
PRNewsWire
2 months ago
CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update
PRINCETON, N.J. , May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31, 2025, and recent business highlights.
Neutral
PRNewsWire
2 months ago
CytoSorbents Provides Regulatory Update for DrugSorb-ATR
PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated Breakthrough Device.
Neutral
PRNewsWire
3 months ago
CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights
PRINCETON, N.J. , April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business highlights after the market close on Wednesday, May 14, 2025.
Neutral
PRNewsWire
3 months ago
CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program
PRINCETON, N.J. , April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds from the sale of its 2023 and amended 2022 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).
Charts implemented using Lightweight Charts™